For the second randomization in CRVO patients , there was no significant difference from week @ BCVA in the ranibizumab plus laser versus the ranibizumab only groups at week @ ( -@ vs. @ letters ) , week @ ( +@ vs. -@ letters ) , or week @ ( +@ vs. -@ letters ) , and a significant increase from week @ mean CST at week @ ( +@ vs. +@ m ; P = @ ) but not weeks @ or @ .